Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Frank-Ulrich Fricke"'
Autor:
Zsuzsanna Ida Petykó, Zoltán Kaló, Jaime Espin, Kateřina Podrazilová, Tomáš Tesař, Nikos Maniadakis, Frank-Ulrich Fricke, András Inotai
Publikováno v:
Cost Effectiveness and Resource Allocation, Vol 19, Iss 1, Pp 1-9 (2021)
Abstract Background Medicines that are based on known molecules and are further developed to address healthcare needs and deliver relevant improvement for patients, healthcare professionals and/or payers are called value-added medicines (VAMs). The e
Externí odkaz:
https://doaj.org/article/8e1bcfec41624ce1940e2ea5de2061f0
Autor:
Zoltán Kaló, Zsuzsanna Ida Petykó, Frank-Ulrich Fricke, Nikos Maniadakis, Tomáš Tesař, Kateřina Podrazilová, Jaime Espin, András Inotai
Publikováno v:
Cost Effectiveness and Resource Allocation, Vol 19, Iss 1, Pp 1-8 (2021)
Abstract Background A core evaluation framework that captures the health care and societal benefits of value added medicines (VAMs, also often called repurposed medicines) was proposed in Report 1, aiming to reduce the heterogeneity in value assessme
Externí odkaz:
https://doaj.org/article/21d9cfc512d44c0598b4a76e7a3c05e0
Autor:
Michele A. Kohli, Michael Maschio, Shannon Cartier, Joaquin Mould-Quevedo, Frank-Ulrich Fricke
Publikováno v:
Vaccines, Vol 10, Iss 9, p 1386 (2022)
Enhanced quadrivalent influenza vaccines that include an adjuvant (aQIV) or a high dose of antigen (QIV-HD), which stimulate a stronger immune response in older adults than the standard vaccine (QIVe), are now approved. The objective of this research
Externí odkaz:
https://doaj.org/article/eb1c4498194a4a01be14f34440de196f
Autor:
Samuel Aballéa, Katia Thokagevistk, Rimma Velikanova, Steven Simoens, Lieven Annemans, Fernando Antonanzas, Pascal Auquier, Clément François, Frank-Ulrich Fricke, Daniel Malone, Aurélie Millier, Ulf Persson, Stavros Petrou, Omar Dabbous, Maarten Postma, Mondher Toumi
Publikováno v:
Journal of Market Access & Health Policy, Vol 8, Iss 1 (2020)
Objective: To provide recommendations for addressing previously identified key challenges in health economic evaluations of Gene Replacement Therapies (GRTs), including: 1) the assessment of clinical effectiveness; 2) the valuation of health outcomes
Externí odkaz:
https://doaj.org/article/94468d6f449f4f42bffe48594a3cb1c3
Autor:
Gérard de Pouvourville, David Cunningham, Frank-Ulrich Fricke, Peter Lindgren, Lorenzo Mantovani, Linda A. Murphy, Oriol Solà-Morales, Jorge Mestre-Ferrandiz, Ron Akehurst
Publikováno v:
Value in Health. 26:3-10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0418675d6209ec4f3104a72d3b81564f
https://doi.org/10.1016/j.jval.2023.01.009
https://doi.org/10.1016/j.jval.2023.01.009
Autor:
Lucia Gozzo, Kenneth Paterson, Olivier Wong, Francis Megerlin, Jan Geldmacher, Patrizia Popoli, Claudio Jommi, Frank-Ulrich Fricke, Oriol De Solà-Morales, Isao Kamae, Guido Rasi, Filippo Drago
Health Technology Assessment (HTA) is a multidisciplinary process which supports policy “decision-making”, including those related to drug reimbursement and price negotiation based on comprehensive clinical and non-clinical evaluations. The discr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcc29bbe913da418150df3d85f7af97a
https://hdl.handle.net/20.500.11769/540140
https://hdl.handle.net/20.500.11769/540140
Autor:
Frank-Ulrich Fricke, Daniel Gottal
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b4f685765a6e16e438f01cefecebd620
https://doi.org/10.2139/ssrn.4113188
https://doi.org/10.2139/ssrn.4113188
Autor:
Tomáš Tesař, Kateřina Podrazilová, Zoltán Kaló, Zsuzsanna Ida Petykó, Frank-Ulrich Fricke, Jaime Espín, Nikos Maniadakis, András Inotai
Publikováno v:
Cost Effectiveness and Resource Allocation : C/E
Cost Effectiveness and Resource Allocation, Vol 19, Iss 1, Pp 1-9 (2021)
Cost Effectiveness and Resource Allocation, Vol 19, Iss 1, Pp 1-9 (2021)
Background Medicines that are based on known molecules and are further developed to address healthcare needs and deliver relevant improvement for patients, healthcare professionals and/or payers are called value-added medicines (VAMs). The evaluation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0166d1a7070bfe9756122bc2d789dd4d
https://hdl.handle.net/10668/18485
https://hdl.handle.net/10668/18485
Autor:
Peter J. Neumann, Michael Drummond, Mondher Toumi, Frank-Ulrich Fricke, Sean D. Sullivan, Sean Tunis, O. Dabbous
Publikováno v:
Value in Health. 22:661-668
The concept of a reference case, first proposed by the US Panel on Cost-Effectiveness in Health and Medicine, has been used to specify the required methodological features of economic evaluations of healthcare interventions. In the case of gene thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21433b9164ee70ced4cf615ef3176e83
https://doi.org/10.1016/j.jval.2019.03.012
https://doi.org/10.1016/j.jval.2019.03.012
Autor:
Daniel C. Malone, Ulf Persson, E Hanna, O. Dabbous, James D. Chambers, Frank-Ulrich Fricke, Sean Tunis, Michael Drummond, Peter J. Neumann, Sean D. Sullivan, Mondher Toumi
Publikováno v:
Health policy (Amsterdam, Netherlands). 125(12)
Transformative cell and gene therapies have now launched worldwide, and many potentially curative cell and gene therapies are in development, offering the prospect of significant health gains for patients. Access to these therapies depend on decision
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ec595c75b6830216d9fcb74a215926f
https://pubmed.ncbi.nlm.nih.gov/34763929
https://pubmed.ncbi.nlm.nih.gov/34763929